Baird lowered the firm’s price target on Regeneron (REGN) to $652 from $759 and keeps a Neutral rating on the shares. The firm said its Eylea ...

Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging.

Nationwide, 58% of Medicare beneficiaries living in rural areas are enrolled in stand-alone prescription drug plans in 2025.

Diabetes is a number of diseases that involve problems with the hormone insulin. There is no cure for diabetes. The warning signs of diabetes can be so mild that you don't notice them. That's ...